INFOR	MATI	ON DIS	SCLOS	URE CI	TATION	AT	TY. DOC	KET NO	D. PC106	64A	SER	IAL NO	. 09/45	1,641	
	(Use several sheets if necessary)						APPLICANT Danchen Gao, et al.								
							FILING DATE November 30, 1999 GROUP 1618								
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME		CLASS	SUBCLASS	FILING UF APPR	DAYE	
	us	5	5	6	3	1	6	5	10/8/96	Talley, et al		514	406		
	us	6	2	3	2	4	2	2	5/15/01	Spitz, et al.		526	351		
										+					

														-	
					-										
					E/	2061	CNDAT	CNT D	CUMEN	Te					
							OITTAI		COMER		Т				
	DOCUMENT NUMBER							DATE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION	
	П		Γ	T	П		Τ		ļ					YES	NO
	EP	0	4	8	8	8	5	6	9/27/95	Europe (English langu equivalent US No. 6,232,422 (above)	Pat	C01F	5/30		х
	wo	0	0	4	8	5	8	3	8/24/00	Internationa		A61P	25/06		
			ОТН	ER DOC	UMENTS	(Inc	luding A	uthor, T	itle, Date,	Pertinent Pag	70s, E	Etc.)	<u> </u>		<u> </u>
	+	Vane, "Towards a better Aspirin", Nature, Vol. 367, pp. 215-216 (1994)													
	4-	Battistini, et al., "COX-1 and COX-2: Toward the Development of More Selective NSAIDs", Drug News and Perspectives, Vol. 7, pp. 501-512 (1994)													
		Statutory Declaration of Professor Ian Tucker, dated January 4, 2003													
		Römpp Cemie Lexikon, 9. Auflage, Band 3, Georg Thieme Verlag, Stuttgart, 1990; pp. 2368-2370													
		Teng, 560 in	Teng, et al., "Formulation dependent pharmacokinetics, bioavailability and renat toxicity of a selective cyclooxygenase-1 inhibitor sc-550 in the rat", J. Pharm. Pharmaceut. Sci. (www.ualberta.ca/~csps), Vol. 6(2); pp. 205-210 (2003)												
			Strickley, "Solubilizing Excipients in Oral and Injectable Formulations". Pharmaceutical Research. Vol. 21(2), po. 201-230 (2004).												
	Strickley, "Solubilizing Excipients in Oral and Injectable Formulations", Pharmaceutical Research, Vol. 21(2), pp. 201-230 (2004)														

INFORMATIO	N DISCLOSURE CITATION	ATTY. DOCK	ET NO. PC10664A	SERIAL NO.	09/451,641			
(Use seve	eral sheets if necessary)	APPLICANT	Danchen Gao, et al.					
		FILING DATE	November 30, 1999	GROUP	1618			
	Waterbeemd, et al., "Estimation of So	lubility, Permeabili	y, Absorption and Bioavailability	", Drug Bioavailability,	Vol. 8, pp. 207-209			
	Davies, et al., "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib A selective Cyclo-Coxygenase-2 Inhibitor", Clin.							
	Pharmacokinet, Vol. 39(3); pp. 225-242 (2000) Barnett International's Strategies for Improving Solubility, Practical Applications for Examining, Measuring, Predicting and Automating Solubility, June 2 – 4, 2004, Airport Marriott, Philladelphia, PA (6 pages) 2004 PSG Technical Conference, Current Pharmaceutical Products, What Was Once Novel is Now Standard, Le Jardin, 8440 Highway 27, Woodbridge, Onlario October 26 – 27, 2004 (8 pages)							
	Memet Bahar, Experimental Protocol pages)	otocol – Crystallization Experiments, Product: Celecoxib; Preparation Date: 03.09-3.09.2004 (5						
	Davies, et al., "Celecoxib: a new optio Pharmacotherapy, Vol. 2(1); pp. 139-	n in the treatment of arthropathies and familial adenomatous polyposis", Expert Opinion on 152 (2001)						
	Declaration of Neal M. Davies dated N	November 17, 2004						
	Declaration of Dr. Tambay Taskin date	ed February 8, 200	6					
	Kesten, "Control and Optimisation of GmbH, D-38678 Clausthal-Zellerfeld,		h Laser Diffraction Particle Size	Analysis and Dry Disp	ersion, Sympatec			
	Clinical Trial Protocol N49-95-02-006, dated September 6, 1995							
	Internal redacted Pfizer document dated July 26, 2007 re: particle size analysis of Arti X 200 mg tablets							
	Consultant Agreement re: Clinical Trial N49-95-02-006 dated September 20, 1995							
	Barber, et al., "A Logical Stepwise Approach to Laser Diffraction Particle Size Distribution Analysis Methods Development and Validation", Pharmacoutical Development and Technology, Vol. 3(2); pp. 153-161 (1998)							
	Pharmaceutical Dosage Forms: Table	2, (1990)						
$\perp \perp \perp \perp$	Jennings, et al., "Particle size measur	ement; the equivale	ent spherical diameter", Proc. R.	Soc. Lond. A, Vol. 41	9, pp. 137-149 (198			
444	United States Provisional Patent Appli	ication No. 60/047,	535, filed May 22, 1997.					
	Affidavit of Professor Shimon Benita .t Products Maabarot Ltd. in Israel (date		e Opposition of Teva Bharmace	uticale, Ltd. And Trim	a-loraeli-Medisel			
	Affidavit of Professor Shimon Benita in Mr. Goren, filed in Israeli opposition (d	late unknown)	avis submitted by G.D. Seane 8	Co. by Professor Jun	gensen, Dr. Davis a			
	Opposition by the Pharmaceutical Inde	ustry Chamber of E	solivia dated October, 2000 (Eng	lish translation)				
	Rejection by Republic of Colombia da	ted March 16, 2005	(English translation)					
	Rejection by Costa Rica dated approx	. 2008, later overco	ome. (English translation)					
	Affidavit of Dr. Cynthia Webb filed on t opposition (date unknown)	hebalf of Teva Pha	rmaceutical Industries Ltd. And	Frima Israeli Medival E	?roducts.i.tdln.israe			
	Affidavit of Professor Avrabari Danon In Israeli opposition (date unknown)	filed on behalf of	Teva Pharmaceutical Industries	Ltd. And Trima Israeli	Medival Products U			
		in	daylis as balled by O.D. O					
	and Mr. Goren, filed in Israeli opposition	on (date unknown)	davite cubmitted by O.D. Coarle	er oo, oy molessor de	rgensen, Dr. Davis			

INFORM	MATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641						
(Us	e several sheets if necessary)	APPLICANT Danchen Gao, et al.							
•	•	FILING DATE November 30, 1999	GROUP 1618						
	Constant fled by Association of Sh								
	Opposition filed by Association of Pharmaceutical Laboratories in Ecuador dated August, 2000 (English Translation) Decision by European Patent Office in Appeal No. T0696/05-3302 dated February 5, 2009 Opposition decision by European Patent Office regarding European Patent No. EP1049467 dated March 30, 2005 Notice of Opposition by Teva Pharmaceutical Industries Ltd. and supporting documents dated July 8, 2003 regarding Patent No. EP1049467								
	Opposition by Zentiva, k.s in Estonia	Opposition by Zentiva, k.s in Estonia dated February 17, 2010 regarding Patent No. EE 04834							
	Oposition by Fako Ltd. in Eurasia regarding Eurasian Patent No. 3363 (English translation)								
	Affidavit of Neal M. Davies, Ph.D. dat	ed March 2006, regarding Guatemalan Patent Application No. PI-990203 and US5,563,165							
	Final Decision filed in Guatemala ord 0203	ering the Registry of Intellectual Property to proceed	d with respective registry regarding PI-19						
	Rejection filed regarding Application	No. PI-990203 in Guatemala dated June 16, 2003							
	Administrative Appeal Brief regarding 2003	Application No. PI-990203 in response to the Guat	emalan Examiner's rejection of June 16,						
	Submission in Guatemala dated April	, 2004							
	Israel opposition summations, July 20	006 (English translation)							
	Opposition Decision by Israel Patent	Office dated February 28, 2008 (English translation)						
	Appeal to Set Aside Refusal of Applic	opine AN:1-1999-02951 dated July 28, 20							
	Notice of Appeal by Teva Pharmaceu June 5, 2009 (English translation)	tical Industries Ltd. and Trima Israeli Medical Produ	icts Maabarot Ltd., filed in Israel, dated						
_	Declaration by Neal M. Davies, Ph.D.	dated November 10, 2004, filed in the Isreal Oppo-	sition						
	Response to Statement filed by the C No. 1999-002453	amara de le Industria Farmaceutica, in Venezuela	regarding Venezuelan Patent Application						
	Annulment Action filed in Peru on Jan	uary 11, 2010							
	Appeal filed by Polpharma in Poland	Appeal filed by Polpharma in Poland regarding Polish Patent No. PL 200957 BI (English Translation)							
	Appeal filed by Zentiva in Poland rega	arding the granting of Patent No.PL 200957 (Englis	h Translation)						
	Decision of Industrial Property Office of the Slovak Republic dated April 26, 2010 regarding Slovak Republic Patent No. SK (English translation) Nullity Action filed by Zentiva in Slovak Republic on July 19, 2008 (English translation) Opposition arguments by Teva Pharmaceuticals in Israel (date unknown) (English translation) Turkish opposition summary by Fako Ilaclari A.S. (June 18, 2001) (English translation)								
	Turkish opposition by Professor. Leve	nt Öner dated June 5, 2001 (English translation)							
	Turkish opposition by TÜM FKIP II A	Turkish opposition by TÜM EKİP İLA, A.S. (2001) (English translation)							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./

INFORMATION DISCLOSURE CITATION				ATTY, DOCKE	T NO. PC10664A	SERIAL NO.	09/451,641		
	(Use	seve	eral sheets if necessary)	APPLICANT	Danchen Gao, et al.	·			
				FILING DATE	November 30, 1999	GROUP	1618		
Turkish opposition by Nobel Ilac Sanayi Ve Ticaret, A.S. dated June 19, 2001 (English translation) Turkish opposition statement by Fako Ilaclari dated June 18, 2001 (English translation)									
EXAMINER			/Susan Tran/	D	ATE CONSIDERED	/Susan Tran/			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation it not in conformance and not considered, include copy of this form with next communication to applicant.									

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /S.T./